NYSE$COR

Cencora Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Reported revenue increase of 9.7 percent year-over-year to $52.5 billion, GAAP diluted EPS of $1.81, and adjusted diluted EPS of $2.18.

AmerisourceBergen reported a strong first quarter in fiscal year 2021, with revenue increasing by 9.7% year-over-year to $52.5 billion. GAAP diluted EPS was $1.81, and adjusted diluted EPS increased by 24% to $2.18. The company raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $8.40 to $8.60.

  • Revenue increased by 9.7% year-over-year to $52.5 billion.
  • GAAP diluted EPS was $1.81, compared to $0.90 in the prior year quarter.
  • Adjusted diluted EPS increased by 24% to $2.18.
  • Adjusted diluted EPS guidance was raised to $8.40 to $8.60 for fiscal year 2021.

Headline financials

Total Revenue

$52.5B

Previous: $47.9B+9.7%
EPS (adj)

$2.18

Previous: $1.76+23.9%
Effective Tax Rate

28.3%

Previous: 18.7%+51.3%
Adj. Effective Tax Rate

22.0%

Previous: 21.0%+4.8%
Capital Expenditures

-$65.4M

Previous: -$67.3M+2.8%
Free Cash Flow

$309M

Previous: $120M+157.1%
Net Income

$375M

Previous: $188M+99.8%
Operating Income

$547M

Previous: $263M+107.7%
Gross Profit

$1.45B

Previous: $1.23B+18.0%
Cash & Equivalents

$4.89B

Previous: $3.23B+51.3%
Total Assets

$45.8B

Previous: $40B+14.6%
Stock-Based Comp

$48.3M

Previous: $31.4M+54.0%

Revenue & EPS history

Cencora · Revenue · Quarterly

$52.5B

Q1 2021+9.7%vs Q1 2020
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Forward guidance

AmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the Company’s continued strong performance and solid execution. This updated financial guidance does not include any contribution from the proposed Alliance Healthcare acquisition or any incremental growth from the expanded U.S. partnership announced in January 2021.

Tailwinds

  • Revenue growth in the high-single digit percent range, up from the mid-single digit percent range.
  • Adjusted Diluted EPS to be in the range of $8.40 to $8.60, up from the previous range of $8.25 to $8.50.
  • Adjusted operating expense growth in the mid- to high-single digit percent range, widened from the mid-single digit percent range.
  • Adjusted operating income growth in the high-single digit percent range, up from the mid-single digit percent range.
  • Pharmaceutical Distribution Services segment operating income growth in the high-single digit percent range, up from the mid-single digit percent range.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

-0.1%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+1.4%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+7.8%

Q2 2019

Best reaction

-18.4%

Q2 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026-18.4%-16.6%-10.1%
Q1 2026-5.9%+0.4%-0.9%
Q4 2025+2.9%+5.8%-1.4%
Q3 2025-2.9%-0.6%+0.1%
Q2 2025+4.6%-4.3%-0.6%
Q1 2025+0.7%-2.1%+1.2%
Q4 2024+5.9%+6.5%+4.0%
Q3 2024+5.8%+4.4%+3.7%
Q2 2024-6.0%-6.3%-5.2%
Q1 2024+7.4%+6.2%+7.5%
Q4 2023+4.2%+4.7%+9.0%
Q3 2023+1.2%-1.3%-7.5%
Q2 2023+0.1%+0.7%+3.5%
Q1 2023-6.2%-8.6%-7.6%
Q4 2022+4.4%+3.1%+12.4%
Q3 2022-2.5%-1.5%+3.4%
Q2 2022+2.9%+4.4%-2.5%
Q1 2022+0.2%+1.3%+7.0%
Q4 2021-0.6%-2.8%-9.0%
Q3 2021-1.5%-2.8%+1.2%
Q2 2021-6.5%-2.1%-7.1%
Q1 2021+3.9%+1.8%-0.7%
Q4 2020-1.0%+4.8%-1.9%
Q3 2020-3.0%-1.6%-7.7%
Q2 2020+3.0%+3.6%+15.8%
Q1 2020-4.8%-2.0%-6.2%
Q4 2019+1.6%+1.0%+4.2%
Q3 2019+3.8%-3.5%-5.6%
Q2 2019+7.8%+5.5%+6.1%
Q1 2019+6.7%+9.2%+5.7%
Q4 2018-2.3%+0.3%-2.9%
Q3 2018+1.9%+5.0%+13.2%
Q2 2018-4.3%-5.1%-6.6%
Q1 2018+2.5%-2.9%+4.7%
Q4 2017-2.4%-2.2%+10.9%
Q3 2017-11.4%-12.0%-12.1%
Q2 2017+3.9%+5.9%+13.2%
Q1 2017+6.0%+6.8%+9.9%
Q4 2016+3.6%+3.1%+12.9%
Q3 2016+5.1%+4.5%+1.9%
Q2 2016-9.2%
Q1 2016-3.7%
Q4 2015-1.0%
Q3 2015-5.4%
Q2 2015+1.9%
Q1 2015+0.4%
Q4 2014+7.1%
Q3 2014+3.7%
Q2 2014-3.1%
Q1 2014-4.3%
Q4 2013+1.8%
Q3 2013-0.0%
Q2 2013-4.6%
Q1 2013-5.1%
Q4 2012-0.6%
Q3 2012+2.7%
Q2 2012-1.2%
Q1 2012+2.4%
Q4 2011-1.0%
Q3 2011-0.5%
Q2 2011+2.9%
Q1 2011+0.5%
Q4 2010-0.5%
Q3 2010-0.7%
Q2 2010+1.0%
Q1 2009-1.7%
Q1 2010+1.2%
Q4 2009-0.6%
Q2 2009-0.6%
Q4 2007-0.6%
Q3 2008-0.5%
Q3 2009-0.5%
Q4 2008-0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro